gender-affirming hormone therapy
Jump to navigation
Jump to search
Epidemiology
- primary medical intervention sought by transgender persons
Indications
Adverse effects
- limits fertility
- discussion of fertility preservation options prior to initiation of gender-affirming hormone therapy[1]
Management
- gender incongruence whose sex recorded as female at birth
- testosterone, including testosterone gel
More general terms
Additional terms
References
- ↑ 1.0 1.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
- ↑ Hembree WC, Cohen-Kettenis PT, Gooren L et al Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869-3903. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28945902
- ↑ Safer JD, Tangpricha V. Care of Transgender Persons. N Engl J Med. 2019 Dec 19;381(25):2451-2460. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31851801 Review. No abstract available. https://www.nejm.org/doi/pdf/10.1056/NEJMcp1903650
- ↑ NEJM Knowledge+ Endocrinology